Sjögren’s Syndrome News

Patients with undiagnosed rheumatic conditions may present symptoms of neurological diseases, creating challenges in making an appropriate diagnosis, according to data published in Current Neurology and Neuroscience Reports.

Nicox S.A. has announced the acquisition of extended North American marketing rights for Sjö, an advanced diagnostic panel used for early detection of Sjögren’s syndrome.

Patients with Sjögren’s syndrome have an elevated risk for MI, particularly in the first year after diagnosis, researchers reported at the European League Against Rheumatism Annual Congress.

Elevated pulse wave velocity and plasma asymmetric dimethylarginine levels in patients with primary Sjögren’s syndrome might be useful markers to detect early endothelial dysfunction and subclinical atherosclerosis, according to study data.

Fecal calprotectin was a biomarker for gastrointestinal disease in patients with systemic sclerosis, when compared with patients with rheumatoid arthritis or primary Sjögren’s syndrome, according to recent research results.

Many smaller, nonrural regions of the United States have no or few practicing rheumatologists, limiting access for patients with chronic rheumatic conditions, according to recent study results.

Nicox today announced the US launch of an advanced diagnostic test for the earlier detection of Sjögren’s syndrome.

OphthaliX recently announced that its parent company, Can-Fite BioPharma, has been granted a patent by the European Patent Office for its drug candidate CF101 for treatment of Sjögren’s syndrome in Europe until 2025.

Determining cut-off levels of beta2-microglobulin and sodium markers in saliva effectively differentiated Sjögren’s syndrome patients from non-Sjögren’s syndrome patients and healthy controls in a recent study.

Nicox has entered into an exclusive agreement with Immco Diagnostics to help promote Immco’s proprietary laboratory test for early detection and diagnosis of Sjögren’s syndrome, according to a press release.